A Study of Darbepoetin Alfa in Patients With Myelodysplastic Syndrome (MDS)
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
hemoglobin and/or red blood cell (RBC) transfusion-dependence.
Peter L Greenberg
United States: Institutional Review Board
|Stanford University School of Medicine||Stanford, California 94305-5317|